BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New CFO Arnd Christ To Take Up Position At MediGene, Inc. In April


4/19/2010 3:26:57 PM

Martinsried/Munich, April 19, 2010. The biotech company MediGene AG (Frankfurt, Prime Standard, TecDAX) today announces that the Company's new Chief Financial Officer Arnd Christ, whose appointment was announced in March, will succeed Dr. Thomas Klaue on April 19, 2010, and Dr. Klaue has therefore resigned with immediate effect. The appointment of Mr Christ was scheduled for May 11, 2010, and the change has become possible earlier because he has been able to terminate his previous employment as Chief Financial Officer at NovImmune AG in mid-April.

Prof. Dr. Ernst-Ludwig Winnacker, Chairman of the Supervisory Board of MediGene AG, commented: "We are delighted to welcome Arnd Christ to MediGene as a respected financial professional with many years of experience in the biotechnology industry. His appointment successfully concludes the re-alignment of MediGene's Executive Board with the company's strategic refocusing which began in 2009. We remain confident in our ongoing drug development programs which are progressing according to schedule, and we would like to invite our shareholders to get a first-hand update of the company's progress at the upcoming annual shareholders meeting."

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the forward-looking statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene is a registered trademark of MediGene. This trademark may be owned or l.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES